The NICE press team issues press releases on all published Clinical Guidelines, Technology Appraisals, and Public Health guidance, as well as for consultations on draft guidance and other news from NICE. Press releases are usually issued under embargo on the day before they are published on the website. If you are a journalist and would like to be added to our mailing list, please send an email to pressoffice@nice.org.uk or call the press team on 0845 003 7782.
|
|
NICE consultation opens on assessing risk of fragility fracture in adults
The National Institute for Health and Clinical Excellence (NICE) today (9 February) opens a consultation on assessing the risk of fragility fracture in adults. The draft short clinical guideline aims to advise on methods to help clinicians assess who might be at risk of a fragility fracture, and will support them in identifying who will benefit from treatments that help prevent such fractures occurring.
February 9, 2012
|
|
NICE consults on new draft guideline on sickle cell
The healthcare guidance body NICE has today (Wednesday 8 February) opened a consultation on the draft of its first guideline on the management of an acute painful sickle cell episode in hospital. Sickle cell is one of the most commonly inherited serious genetic disorders in England.
February 8, 2012
|
|
Draft NICE guidance says more evidence needed on new tests to guide breast cancer treatment decisions
Draft guidance from NICE on four tests used to guide decisions about the use of chemotherapy in women with early breast cancer recommends that the IHC4 test is used in a research setting to collect evidence on a range of potentially important outcomes in patients with early breast cancer.
February 3, 2012
|
|
NICE consults on a new treatment for prostate cancer
NICE, the healthcare guidance body, has issued new draft guidance not recommending the use of abiraterone (Zytiga, Janssen) in combination with prednisone or prednisolone for the treatment of castration-resistant[1] metastatic prostate cancer that has progressed on or after docetaxel-containing therapy.
February 2, 2012
|
|
2013/14 COF consultation opens
NICE has today launched its first consultation on potential indicators for the proposed 2013/14 Commissioning Outcomes Framework (COF). Anyone with an interest in health is invited to comment on the 120 indicators, which cover a broad range of topics, including mental health, cancer and asthma.
February 1, 2012
|
|
Increase monitoring for severe asthma treatment, says NICE
Doctors who are considering offering a treatment for severe asthma, which involves heating the tissue of the lung airways, should take special care when deciding who to offer the procedure to and ensure that patients are fully informed about what is involved. This is because NICE has said that further research is still needed to show that the procedure is safe and clinically effective in the long term.
January 25, 2012
|
|
NICE guidance on new generation cardiac CT scanners set to improve diagnosis and management of coronary artery disease
NICE has published guidance as part of its diagnostics assessment programme supporting the use of four new generation cardiac computed tomography (CT) scanners for people with suspected or known coronary artery disease (CAD) in whom imaging is difficult with earlier generation CT scanners.
January 25, 2012
|
|
NICE approves new drug to prevent blood clots after hip and knee surgery
NICE has published final guidance recommending the use of apixaban (Eliquis, Bristol-Myers Squibb and Pfizer) as an option for the prevention of venous thromboembolism (VTE) in adults who have undergone planned total hip replacement or total knee replacement surgery.
January 25, 2012
|
|
NICE recommends new treatment for CML
NICE, the healthcare guidance body, has today published final guidance recommending a new treatment for chronic myeloid leukaemia (CML).
January 13, 2012
|
|
NICE gives green light to prolonged-release exenatide for type 2 diabetes in final draft guidance
In final draft guidance published today (Friday 13 January) NICE, the healthcare guidance body, has confirmed its initial draft recommendation of prolonged release exenatide (Bydureon, Eli Lilly) in triple therapy regimens (in combination with metformin and a sulphonylurea, or metformin and a thiazolidinedione) as a treatment option for some people with type 2 diabetes.
January 13, 2012
|
This page was last updated: 09 February 2012
